ResearcherUniversity of California, Los AngelesActive in the last 2 years
Evan R. Abt
Matched on ORCID iD 0000-0002-3160-7134; OpenAlex author ID A5066633792. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Co-author DOI 10.1038/s41467-026-68976-2↗
- MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signaling. Co-author DOI 10.1158/1078-0432.ccr-22-3322↗
- Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Co-author DOI 10.1016/j.celrep.2021.110236↗
- NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. Co-author DOI 10.1073/pnas.2012469118↗
- Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Co-author DOI 10.1073/pnas.1812410116↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Timothy R. Donahue · 5 shared papers, 2019–2026 · strength 0.64
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signal… DOI 10.1158/1078-0432.ccr-22-3322↗
- Paper Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in p… DOI 10.1016/j.celrep.2021.110236↗
- Caius Gabriel Radu · 5 shared papers, 2019–2026 · strength 0.64
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signal… DOI 10.1158/1078-0432.ccr-22-3322↗
- Paper Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in p… DOI 10.1016/j.celrep.2021.110236↗
- Jason M. Link · 3 shared papers, 2022–2026 · strength 0.47
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signal… DOI 10.1158/1078-0432.ccr-22-3322↗
- Paper Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in p… DOI 10.1016/j.celrep.2021.110236↗
- David W. Dawson · 3 shared papers, 2021–2026 · strength 0.42
- Paper Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase… DOI 10.1038/s41467-026-68976-2↗
- Paper Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in p… DOI 10.1016/j.celrep.2021.110236↗
- Paper NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. DOI 10.1073/pnas.2012469118↗
- Keke Liang · 3 shared papers, 2021–2023 · strength 0.36
- Paper MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signal… DOI 10.1158/1078-0432.ccr-22-3322↗
- Paper Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in p… DOI 10.1016/j.celrep.2021.110236↗
- Paper NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. DOI 10.1073/pnas.2012469118↗
- Razmik Ghukasyan · 3 shared papers, 2019–2023 · strength 0.32
- Paper MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signal… DOI 10.1158/1078-0432.ccr-22-3322↗
- Paper NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. DOI 10.1073/pnas.2012469118↗
- Paper Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. DOI 10.1073/pnas.1812410116↗
- Jing Cui · 2 shared papers, 2021–2022 · strength 0.21
- Zev A. Wainberg · 1 shared paper, 2026 · strength 0.21
- Shineui Kim · 1 shared paper, 2026 · strength 0.21
- Michael K. Srienc · 1 shared paper, 2026 · strength 0.21
- Jonathan C. King · 1 shared paper, 2026 · strength 0.21
- Oscar Joe Hines · 1 shared paper, 2026 · strength 0.21
- Irmina A. Elliott · 2 shared papers, 2019–2021 · strength 0.17
- Alexandra M. Moore · 2 shared papers, 2019–2021 · strength 0.17
- Joon Y. Park · 1 shared paper, 2023 · strength 0.15
- Johannes Czernin · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.